Sangamo BioSciences CFO Henry Ward Wolff Sells 10,000 Shares (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) CFO Henry Ward Wolff unloaded 10,000 shares of Sangamo BioSciences stock on the open market in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $10.86, for a total transaction of $108,600.00. Following the transaction, the chief financial officer now directly owns 209,219 shares of the company’s stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on SGMO shares. Analysts at Zacks upgraded shares of Sangamo BioSciences (NASDAQ:SGMO) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 30th. They now have a $10.50 price target on the stock. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Sangamo BioSciences (NASDAQ:SGMO) in a research note to investors on Monday, June 17th.
One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $16.70.
Shares of Sangamo BioSciences (NASDAQ:SGMO) traded down 0.66% during mid-day trading on Thursday, hitting $10.50. The stock had a trading volume of 332,375 shares. Sangamo BioSciences has a 52-week low of $4.92 and a 52-week high of $11.32. The stock has a 50-day moving average of $10.07 and a 200-day moving average of $9.2. The company’s market cap is $568.1 million.
Sangamo BioSciences (NASDAQ:SGMO) last announced its earnings results on Wednesday, July 24th. The company reported ($0.10) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.12) by $0.02. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $4.77 million. During the same quarter last year, the company posted ($0.11) earnings per share. Sangamo BioSciences’s revenue was up 50.0% compared to the same quarter last year. Analysts expect that Sangamo BioSciences will post $-0.44 EPS for the current fiscal year.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.